<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0201244652
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        EMCAST 4 MG CHEWABLE TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MONTELUKAST SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Chewable tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        64.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Med city" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Med city
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Med City Pharma
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03DC03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>What Emcast&reg; is</strong><br /><strong>Emcast&reg;</strong> is a leukotriene receptor antagonist that blocks substances called leukotrienes.<br />How<strong> Emcast&reg;</strong> works<br />Leukotrienes cause narrowing and swelling of airways in the lungs. By blocking<br />leukotrienes, <strong>Emcast&reg;</strong> improves asthma symptoms and helps control asthma.<br /><strong>When Emcast&reg; should be used</strong><br />Your child&rsquo;s doctor has prescribed Emcast&reg; to treat your child&rsquo;s asthma, preventing<br />asthma symptoms during the day and night.<br /><strong>&bull; Emcast&reg;</strong> is used for the treatment of 2 to 5 year old patients who are not adequately<br />controlled on their medication and need additional therapy.<br /><strong>&bull; Emcast&reg;</strong> may also be used as an alternative treatment to inhaled corticosteroids for 2<br />to 5 year old patients who have not recently taken oral corticosteroids for their asthma<br />and have shown that they are unable to use inhaled corticosteroids.<br /><strong>&bull; Emcast&reg;</strong> also helps prevent the narrowing of airways triggered by exercise for<br />patients 2 years of age and older.<br />Your child&rsquo;s doctor will determine how Emcast&reg; should be used depending on the<br />symptoms and severity of your child&rsaquo;s asthma.<br /><strong>What is asthma?</strong><br />Asthma is a long-term disease.<br />Asthma includes:<br />&bull; Difficulty breathing because of narrowed airways. This narrowing of airways worsens<br />and improves in response to various conditions.<br />&bull; Sensitive airways that react to many things, such as cigarette smoke, pollen, cold air,<br />or exercise.<br />&bull; Swelling (inflammation) in the lining of the airways.<br />Symptoms of asthma include: Coughing, wheezing, and chest tightness.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Tell your child&rsquo;s doctor about any medical problems or allergies your child has now or has had.<br /><strong>Do not give Emcast&reg; to your child</strong><br />&bull; If he/she is allergic to montelukast or any of the other ingredients of this medicine.<br /><strong>Warnings and precautions</strong><br />Talk to your child&rsquo;s doctor or pharmacist before you give Emcast&reg; to your child.<br />&bull; If your child&rsquo;s asthma or breathing gets worse, tell your child&rsquo;s doctor immediately.<br />&bull; <strong>Oral Emcast&reg;</strong> is not meant to treat acute asthma attacks. If an attack occurs, follow<br />the instructions your child&rsquo;s doctor has given you for your child. Always have your<br />child&rsquo;s inhaled rescue medicine for asthma attacks with you.<br />&bull; It is important that your child take all asthma medications prescribed by your child&rsquo;s<br />doctor. <strong>Emcast&reg;</strong> should not be used instead of other asthma medications your child&rsquo;s<br />doctor has prescribed for your child.<br />&bull; If your child is on anti-asthma medicines, be aware that if he/she develops a<br />combination of symptoms such as flu-like illness, pins and needles or numbness of<br />arms or legs, worsening of pulmonary symptoms, and/or rash, you should consult your<br />child&rsquo;s doctor.<br />&bull; Your child should not take acetyl-salicylic acid (aspirin) or anti-inflammatory<br />medicines (also known as non-steroidal anti-inflammatory drugs or NSAIDs) if they<br />make his/her asthma worse.<br /><strong>Children and adolescents</strong><br />Do not give this medicine to children less than 2 years of age.<br />There are different form(s) of this medicine available for paediatric patients under 18<br />years of age based on age range.<br /><strong>Other medicines and Emcast&reg;</strong><br />Tell child&rsquo;s doctor or pharmacist if your child is taking or has recently been given or<br />might be given any other medicines including those obtained without a prescription.<br />Some medicines may affect how <strong>Emcast&reg;</strong> works, or <strong>Emcast&reg;</strong> may affect how your<br />child&rsquo;s other medicines work.<br />Tell child&rsquo;s doctor if your child is taking the following medicines before starting<br /><strong>Emcast&reg;</strong>:<br />&bull; Phenobarbital (used for treatment of epilepsy).<br />&bull; Phenytoin (used for treatment of epilepsy).<br />&bull; Rifampicin (used to treat tuberculosis and some other infections).<br /><strong>Emcast&reg;</strong> <strong>with food and drink</strong><br /><strong>Emcast&reg; 4 mg</strong> chewable tablets should not be taken immediately with food; they<br />should be taken at least 1 hour before or 2 hours after food.<br /><strong>Pregnancy and breast-feeding</strong><br />This subsection is not applicable for the <strong>Emcast&reg; 4 mg</strong> chewable tablets since they are<br />intended for use in children 2 to 5 years of age.<br /><strong>Driving and using machines</strong><br />This subsection is not applicable for the <strong>Emcast&reg; 4 mg</strong> chewable tablets since they are<br />intended for use in children 2 to 5 years of age, however the following information is<br />relevant to the active ingredient, montelukast.<br /><strong>Emcast&reg;</strong>&nbsp;is not expected to affect your ability to drive a car or operate machinery.<br />However, individual responses to medication may vary. Certain side effects (such as<br />dizziness and drowsiness) that have been reported with Emcast&reg; may affect some<br />patients&rsquo; ability to drive or operate machinery.<br /><strong>Emcast&reg; 4 mg chewable tablets contain Lactose monohydrate</strong><br />If you have been told by your child&rsquo;s doctor that your child has an intolerance to some<br />sugars, contact your child&rsquo;s doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Always give your child this medicine exactly as your child&rsquo;s doctor or pharmacist has<br />told you. Check with your child&rsquo;s doctor or pharmacist if you are not sure.<br />&bull; This medicine is to be given to a child under adult supervision. For children who have<br />problems consuming a chewable tablet, an oral granule formulation of montelukast<br />is available.<br />&bull; Your child should take only one chewable tablet of<strong>Emcast&reg; </strong>once a day as prescribed<br />by your child&rsquo;s doctor.<br />&bull; It should be taken even when your child has no symptoms or if he/she has an acute<br />asthma attack.<br /><strong>For children 2 to 5 years of age:</strong><br />The recommended dose is one <strong>Emcast&reg; 4 mg</strong> chewable tablet daily to be taken in the<br />evening.<br />If your child is taking <strong>Emcast&reg;</strong>, be sure that he/she does not take any other medicinesthat contain the same active ingredient, montelukast.<br />This medicine is for oral use.<br />The tablets are to be chewed before swallowing.<br /><strong>Emcast&reg; 4 mg</strong> chewable tablets should not be taken immediately with food; it should<br />be taken at least 1 hour before or 2 hours after food.<br /><strong>If you give your child more Emcast&reg; than you should</strong><br />Contact your child&rsquo;s doctor immediately for advice.<br />There were no side effects reported in the majority of overdose reports. The most<br />frequently occurring symptoms reported with overdose in adults and children included<br />abdominal pain, sleepiness, thirst, headache, vomiting, and hyperactivity.<br /><strong>If you forget to give Emcast&reg; to your child</strong><br />Try to give Emcast&reg; as prescribed. However, if your child misses a dose, just resume<br />the usual schedule of one chewable tablet once daily.<br />Do not give a double dose to make up for a forgotten dose.<br /><strong>If you stop giving Emcast&reg; to your child</strong><br />Emcast&reg; can treat your child&rsquo;s asthma only if you continue giving it.<br />It is important for your child to continue taking <strong>Emcast&reg;</strong> for as long as your child&rsquo;s<br />doctor prescribes. It will help control your child&rsquo;s asthma.<br />If you have any further questions on the use of this medicine, ask your child&rsquo;s doctor<br />or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, this medicine can cause side effects, although not everybody<br />gets them.<br />In clinical studies with montelukast 4 mg chewable tablets, the most commonly<br />reported side effects (occurring in at least 1 of 100 patients and less than 1 of 10<br />paediatric patients treated) thought to be related to montelukast were:<br />&bull; Abdominal pain.<br />&bull; Thirst.<br />Additionally, the following side effect was reported in clinical studies with<br />montelukast 10 mg film-coated tablets and 5 mg chewable tablets:<br />&bull; Headache.<br />These were usually mild and occurred at a greater frequency in patients treated with<br />montelukast tablets than placebo (a pill containing no medication).<br />The frequency of possible side effects listed below is defined using the following<br />convention:<br />Very common: may affect more than 1 in 10 people<br />Common: may affect up to 1 in 10 people<br />Uncommon: may affect up to 1 in 100 people<br />Rare: may affect up to 1 in 1,000 people<br />Very rare: may affect up to 1 in 10,000 people<br />Not known: frequency cannot be estimated from the available data<br />Additionally, while the medicine has been on the market, the following have been<br />reported:<br />&bull; Upper respiratory infection (<em>Very common</em>).<br />&bull; Increased bleeding tendency (<em>Rare</em>).<br />&bull; Allergic reactions including swelling of the face, lips, tongue, and/or throat which<br />may cause difficulty in breathing or swallowing (<em>Uncommon</em>).<br />&bull; Behaviour and mood related changes [dream abnormalities, including nightmares,<br />trouble sleeping, sleep walking, irritability, feeling anxious, restlessness, agitation<br />including aggressive behaviour or hostility, depression (<em>Uncommon</em>); tremor,<br />disturbance in attention, memory impairment (Rare); hallucinations, disorientation,<br />suicidal thoughts and actions (<em>Very rare</em>)].<br />&bull; Dizziness, drowsiness, pins and needles/numbness, seizure (<em>Uncommon</em>).<br />&bull; Palpitations (<em>Rare</em>).<br />&bull; Nosebleed (<em>Uncommon</em>), swelling (inflammation) of the lungs (Very rare).<br />&bull; Diarrhea, nausea, vomiting (<em>Common</em>); dry mouth, indigestion (<em>Uncommon</em>).<br />&bull; Hepatitis (inflammation of the liver) (<em>Very rare</em>).<br />&bull; Rash (<em>Common</em>); bruising, itching, hives (Uncommon); tender red lumps under<br />the skin most commonly on your shins (erythema nodosum), severe skin reactions<br />(erythema multiforme) that may occur without warning (<em>Very rare</em>).<br />&bull; Joint or muscle pain, muscle cramps (<em>Uncommon</em>).<br />&bull; Fever (<em>Common</em>); weakness/tiredness, feeling unwell, swelling (<em>Uncommon</em>).<br />In asthmatic patients treated with montelukast, very rare cases of a combination of<br />symptoms such as flu-like illness, pins and needles or numbness of arms and legs,<br />worsening of pulmonary symptoms and/or rash (Churg-Strauss syndrome) have been<br />reported. You must tell your child&rsquo;s doctor right away if your child gets one or more<br />of these symptoms.<br />If your child gets any side effects, talk to your child&rsquo;s doctor, pharmacist or nurse.<br />This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Keep out of reach and sight of children.<br />Do not use this medicine after the expiry date which is stated on the blister and the<br />carton.<br />The expiry date refers to the last day of that month.<br /><strong>Emcast&reg;</strong> Chewable Tablets :Store below 30 &deg;C.<br />Medicine should not be disposed of via wastewater or household waste. Ask your<br />pharmacist how to dispose of medicines no longer required. These measures will help<br />to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">What Emcast&reg; Tablets contains<br />&bull; The active substance is: Montelukast (sodium).<br />&bull; The other ingredients are: Microcrystalline cellulose (Avicel) PH102, lactose<br />monohydrate, mannitol EZ, croscarmellose sodium, cherry powder flavor, red iron<br />oxide, acesulfame K, magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Emcast® tablets look like and contents of the pack
Emcast® 4 mg chewable tablets are Pink oval normal biconvex tablets engraved
with MD on one face and M3 on the other face, presented in Alu/Alu blisters,
intended for oral use.
Pack size:
30 Chewable Tablets. 10 tablets/blister, 3 blisters/pack.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Med City Pharma - KSA</strong><br />Tel: 00966920003288<br />Fax: 00966126358138<br />Mobile: 00966555786968<br />P.O .Box: 42512 - Jeddah 21551<br />E-mail: MD.admin@Axantia.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                07/2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>ما هو إمكاست &reg;</strong><br />يعد <strong>إمكاست &reg;</strong> مضاد لمستقبل ليوكوتراين الذي يعمل على حصر مواد تسمى ليوكوتراينات.<br /><strong>طريقة عمل إمكاست &reg;</strong><br />تسبب الليوكوتراينات تضيق وتورم المجاري الهوائية في الرئتين. وعن طريق حصر الليوكوتراينات،<br />يحسن <strong>إمكاست &reg;</strong> أعراض الربو ويساعد في السيطرة على حالة الربو.<br /><strong>الوقت المناسب لاستعمال إمكاست &reg;</strong><br />لقد قام الطبيب بوصف إمكاست &reg; لعلاج الربو لدى طفلك، ولمنع ظهور أعراض الربو خلال النهار والليل.<br />&bull;يستعمل <strong>إمكاست &reg;</strong> لعلاج المرضى الذين تتراوح أعمارهم بين 2 إلى 5 أعوام ولم يتم السيطرة على حالتهم<br />باستعمال أدويتهم الحالية ويحتاجون إلى علاج إضافي.<br />&bull;قد يستعمل <strong>إمكاست &reg;</strong> أيضا كعلاج بديل للستيرويدات القشرية التي يتم استنشاقها، للمرضى الذين تتراوح<br />أعمارهم بين 2 إلى 5 أعوام ولم يتناولوا مؤخرا ستيرويدات قشرية عن طريق الفم لعلاج الربو لديهم<br />وأظهروا عدم قدرتهم على استعمال الستيرويدات القشرية التي يتم استنشاقها.<br />&bull;يساعد <strong>إمكاست &reg;</strong> أيضا على منع حدوث تضيق في المجاري الهوائية ناتج عن القيام بالتمارين الرياضية.<br />سيحدد طبيب طفلك كيفية استعمال <strong>إمكاست &reg;</strong> اعتمادا على الأعراض و حدة حالة الربو لدى طفلك.<br /><strong>ما هو الربو؟</strong><br />يعد الربو مرض طويل الأمد.<br />يتضمن الربو ما يلي:<br />&bull;صعوبة في التنفس نتيجة تضيق المجاري الهوائية. يزداد تضيق المجاري الهوائية سوءا ويتحسن حسب<br />الاستجابة لظروف مختلفة.<br />&bull;المجاري الهوائية الحساسة التي تتأثر بعدة عوامل مثل دخان السجائر، حبوب اللقاح، الهواء البارد، أو<br />التمارين الرياضية.<br />&bull;تورم (التهاب) في بطانة المجاري الهوائية.<br />تتضمن أعراض الربو: سعال، أزيز تنفسي، والإحساس بضيق في الصدر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>أخبر طبيب طفلك عن أي مشاكل طبية أو تحسسية قد يعاني منها طفلك في الوقت الحالي أو عانى منها<br />في السابق.<br />الحالات التي يجب أن لا تعطي فيها طفلك<strong> إمكاست&reg;</strong> :<br />&bull;إذا كان هو/هي يعاني من تحسس لمونتيلوكاست أو لأي مكونات أخرى في هذا الدواء.<br /><strong>الاحتياطات والمحاذير</strong><br />أخبر طبيب طفلك أو الصيدلي قبل إعطاء <strong>إمكاست &reg;</strong> لطفلك.<br />&bull;إذا كانت حالة الربو أو التنفس لدى طفلك تزداد سوءا، أخبر طبيب طفلك فورا.<br />&bull;إن تناول <strong>إمكاست &reg;</strong> عن طريق الفم لا يعني أنه يستعمل لعلاج نوبات الربو الحادة. إذا حدثت نوبة، اتبع<br />تعليمات طبيب طفلك التي أعطاها لك. دائما احتفظ بأدوية الانقاذ التي يستنشقها طفلك في حالة حدوث<br />نوبات الربو.<br />&bull;من الضروري أن يتناول طفلك جميع أدوية الربو التي وصفها الطبيب. يجب عدم استعمال إمكاست &reg;<br />بدلا من أدوية الربو الأخرى التي وصفها الطبيب لطفلك.<br />&bull;إذا كان طفلك يتناول أدوية مضادة للربو، كن حذرا في حالة الإصابة بمجموعة من الأعراض مثل مرض<br />يشبه الإنفلونزا، الإحساس بوخز خفيف أو تنميل الذراعين أو الساقين، زيادة حالة الأعراض التنفسية سوءا<br />و/أو طفح، يجب استشارة طبيب طفلك.<br />&bull;يجب أن لا يتناول طفلك حمض الأسيتيل ساليساليك الأسبرين أو الأدوية المضادة للالتهاب تعرف&nbsp;<br />أيضا بالأدوية غير الستيرويدية المضادة للالتهاب إذا كانت هذه الأدوية تزيد حالة الربو لديه هو/هي سوءا.<br /><strong>الأطفال والمراهقون</strong><br />لا تعطي هذا الدواء للأطفال الذين تقل أعمارهم عن عامين.<br />تتوفر أشكال مختلفة من هذا الدواء تستعمل للمرضى الأطفال الذين تقل أعمارهم عن 18 عاما اعتمادا<br />على الفئة العمرية.<br /><strong>تناول أدوية أخرى مع إمكاست &reg;</strong><br />أخبر طبيب طفلك أو الصيدلي إذا كان طفلك يتناول أو تم إعطاؤه مؤخراً أو من الممكن إعطائه أي أدوية<br />أخرى، بما في ذلك الأدوية التي يتم الحصول عليها بدون وصفة طبية.<br />قد تؤثر بعض الأدوية على آلية عمل <strong>إمكاست &reg;</strong>، أو قد يؤثر <strong>إمكاست &reg;</strong> على آلية عمل الأدوية الأخرى التي<br />يتناولها طفلك.<br />أخبر طبيب طفلك إذا كان طفلك يتناول الأدوية التالية قبل البدء بتناول <strong>إمكاست &reg;</strong> :<br />&bull;فينوباربيتال (يستعمل لعلاج الصرع)&nbsp;.&nbsp;<br />&bull;فينيتوين (يستعمل لعلاج الصرع) .&nbsp;<br />&bull;ريفامبيسين (يستعمل لعلاج السل وبعض الالتهابات الأخرى) .&nbsp;<br />تناول إمكاست &reg; مع الطعام والشراب<br />يجب عدم تناول أقراص <strong>إمكاست &reg;</strong> 4&nbsp;ملغم القابلة للمضغ مباشرة مع الطعام، ويجب تناولها قبل ساعة على الأقل أو بعد ساعتين من تناول الطعام.<br /><strong>الحمل والرضاعة الطبيعية</strong><br />لا ينطبق هذا القسم على أقراص <strong>إمكاست &reg;</strong> 4 ملغم القابلة للمضغ حيث أنها تستعمل للأطفال الذين تتراوح أعمارهم بين 2 إلى 5 أعوام.<br /><strong>القيادة و استخدام الآلات</strong><br />لا ينطبق هذا القسم على أقراص <strong>إمكاست &reg;</strong> 4 ملغم القابلة للمضغ حيث أنها تستعمل للأطفال الذين تتراوح أعمارهم بين 2 إلى 5 أعوام، لكن المعلومات التالية تتعلق بالمادة الفعالة، مونتيلوكاست.<br />من غير المتوقع أن يؤثر <strong>إمكاست &reg;</strong> على قدرتك على القيادة أواستخدام الآلات. لكن، قد تختلف الاستجابات<br />الفردية للدواء. تم تسجيل حدوث آثار جانبية معينة قد تؤثر على قدرة بعض المرضى على القيادة أوتشغيل<br />الآلات مثل الشعور بالدوار والنعاس عند تناول <strong>إمكاست &reg;</strong>&nbsp;.<br /><strong>تحتوي أقراص إمكاست &reg; 4 ملغم القابلة للمضغ على لاكتوز مونوهيدرات</strong><br />إذا أخبرت من قبل طبيب طفلك أن طفلك لا يستطيع تحمل بعض أنواع السكريات، اتصل مع طبيب طفلك<br />قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">&nbsp; دائما قم بإعطاء طفلك هذا الدواء تماما كما أخبرك طبيب طفلك أو الصيدلي. تأكد من طبيب طفلك أو الصيدلي إذا لم تكن متأكدا.</p><ul><li>يجب إعطاء هذا الدواء للطفل تحت إشراف أحد البالغين. للأطفال الذين يعانون من مشاكل في تناول الأقراص القابلة للمضغ، تتوفر تركيبة حبيبات يتم تناولها عن طريق الفم من مونتيلوكاست. &nbsp;</li><li>&nbsp;يجب أن يتناول طفلك قرص واحد فقط من أقراص <strong>إمكاست &reg;</strong>&nbsp;القابلة للمضغ مرة واحدة يوميا كما وصف&nbsp;طبيب طفلك &bull;</li><li>&nbsp;يجب تناوله حتى إذا لم يكن طفلك يعاني من أعراض أو إذا كان هو/هي يعاني من نوبة ربو حادة.</li></ul><p>&nbsp;<strong>للأطفال الذين تتراوح أعمارهم بين&nbsp;2 الى5 أعوام:</strong></p><p dir="ltr">&nbsp; الجرعة الموصى بها هي قرص واحد من أقراص <strong>إمكاست &reg;</strong> 4&nbsp;ملغم القابلة للمضغ يوميا يتم تناولها&nbsp;في&nbsp;</p><p>المساء.</p><p>اذا كان طفلك يتناول&nbsp;<strong>إمكاست &reg;&nbsp;</strong>تأكد من عدم تناوله هو/هي أي أدوية أخرى تحتوي على نفس المادة الفعالة، مونتيلوكاست.</p><p>إن هذا الدواء&nbsp;معد للاستعمال عن طريق الفم.</p><p>يجب مضغ الأقراص قبل بلعها.</p><p>يجب عدم تناول أقراص ملغم القابلة للمضغ مباشرة مع الطعام، ويجب تناولها قبل ساعة على&nbsp;إمكاست الأقل أو بعد ساعتين من تناول الطعام .</p><p><strong>إذا تم إعطاء طفلك إمكاست &reg; أكثر مما يجب</strong></p><p>اتصل بطبيب طفلك فورا للاستشارة.</p><p>لم يتم تسجيل حدوث آثار جانبية في معظم حالات فرط الجرعة. الأعراض الأكثر تكرارا التي تم تسجيلها في حالة فرط الجرعة عند البالغين والأطفال والتي تضمنت ألم في البطن، الشعور بالنعاس، العطش، صداع، قيء، وفرط النشاط.</p><p><strong>إذا نسيت إعطاء طفلك جرعة إمكاست &reg; </strong></p><p>حاول أن تعطي <strong>إمكاست &reg;&nbsp;</strong>كما هو موصوف. لكن، إذا نسيت إعطاء جرعة، فقط استمر في الجرعات كالمعتاد بإعطاء قرص واحد يوميا.</p><p>لا تعطي طفلك جرعة مضاعفة لتعويض الجرعة التي نسيتها.</p><p><strong>إذا توقفت عن إعطاء إمكاست&reg; لطفلك&nbsp; </strong></p><p>&nbsp;قد يعالج <strong>إمكاست&reg;</strong> حالة الربو لدى طفلك فقط إذا استمريت في إعطائه هذا الدواء.</p><p>من الضروري أن يستمر طفلك في تناول <strong>إمكاست&reg;&nbsp;</strong>طالما يصفه طبيب طفلك. سيساعد ذلك في السيطرة&nbsp;على حالة الربو لدى طفلك.</p><p>إذا كان لديك أي أسئلة إضافية عن استعمال هذا المستحضر، إسأل طبيب طفلك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، ويمكن أن يتسبب <strong>إمكاست&reg;</strong> في حدوث آثار جانبية، على الرغم من أنها قد لا تحصلعند الجميع.<br />خلال الدراسات السريرية المتعلقة بأقراص مونتيلوكاست 4 ملغم القابلة للمضغ، كانت الآثار الجانبية<br />الأكثر شيوعا التي تم تسجيلها (تحصل عند 1 على الأقل من كل 100 مريض و عند أقل من 1 من كل<br />10 مرضى من الأطفال الذين تم علاجهم بمونتيوكاست) والتي يعتقد أن لها علاقة بمونتيلوكاست كما يلي:&nbsp;<br />&bull;ألم في البطن.<br />&bull;عطش.<br />بالإضافة لذلك، تم تسجيل الاثار الجانبية التالية خلال الدراسات السريرية المتعلقة بأقراص مونتيلوكاست<br />10 ملغم المغلفة و أقراص مونتيلوكاست 5 ملغم القابلة للمضغ:<br />&bull;صداع.<br />كانت هذه الآثار الجانبية عادة معتدلة وحصلت بتكرار أكبر عند المرضى الذين تم علاجهم بأقراص<br />مونتيلوكاست من أولئك الذين تم علاجهم بالأقراص التي لا تحتوي على المادة الفعالة.<br />تصنف الآثار الجانبية المحتملة المذكورة في الأسفل حسب التقسيمات التالية:<br />شائعة جدا: قد تؤثر على أكثر من 1 من كل 10 أشخاص<br />شائعة: قد تؤثر على 1 أو أقل من كل 10 أشخاص<br />غير شائعة: قد تؤثر على 1 أو أقل من كل 100 شخص<br />نادرة: قد تؤثر على 1 أو أقل من كل 1000 شخص<br />نادرة جدا: قد تؤثر على 1 أو أقل من كل 10000 شخص<br />غير معروفة: لا يمكن تقدير تكرار حدوثها من المعلومات المتوفرة<br />بالإضافة لذلك، خلال فترة تسويق الدواء، تم تسجيل حدوث الآثار الجانبية التالية:<br />&bull;التهاب الجهاز التنفسي العلوي (شائعة جدا) .&nbsp;<br />&bull;زيادة التعرض للنزيف (نادرة) .<br />&bull;تفاعلات تحسسية تتضمن تورم الوجه، الشفاه، اللسان، و/أو الحلق الذي قد يسبب صعوبة في التنفس<br />أو البلع (غير شائعة) .&nbsp;<br />&bull;تغيرات متعلقة بالسلوك والمزاج (اضطرابات الأحلام، بما في ذلك الكوابيس، صعوبة القدرة على&nbsp;<br />النوم، المشي أثناء النوم، سرعة الغضب، الشعور بالقلق، عدم الراحة، هياج بما في ذلك سلوك عدواني أو<br />العدائية، اكتئاب(غير شائعة) ، رعاش، اضطراب في الانتباه، ضعف الذاكرة (نادرة) ، هلوسات، ارتباك،&nbsp;<br />التفكير بالانتحار والإقدام عليه (نادرة جدا)).<br />&bull;الشعور بالدوار، النعاس، الإحساس بوخز خفيف/تنميل، نوبات الصرع (غير شائعة).&nbsp;<br />&bull;خفقان (نادرة) .&nbsp;<br />&bull;نزيف في الأنف (غير شائعة) ، تورم (التهاب) الرئتين (نادرة جدا) .&nbsp;<br />&bull;إسهال، شعور بالغثيان، قيء (شائعة) ، جفاف الفم، عسر الهضم غ(غير شائعة) .&nbsp;<br />&bull;التهاب الكبد (نادرة جدا) .<br />&bull;طفح (شائعة) ، التعرض للكدمات، حكة، شرى (غير شائعة) ، بروز كتل حمراء تحت الجلد تشعر&nbsp;<br />بالألم عند لمسها بشكل أكثر شيوعا على الساقين (حمامى عقدية) ، تفاعلات جلدية حادة (حمامى متعددة<br />الأشكال) التي قد تحدث مع أو بدون ظهور أعراض تحذيرية (نادرة جدا).&nbsp;<br />&bull;ألم في المفاصل أو العضلات، تشنج العضلات (غير شائعة) .&nbsp;<br />&bull;حمى (شائعة) ، الشعور بالضعف/التعب، الشعور بالمرض، تورم (غير شائعة) .&nbsp;<br />عند المرضى الذي يعانون من الربو وتم علاجهم بمونتيلوكاست، تم تسجيل حدوث حالات نادرة جدا من<br />مجموعة أعراض مثل مرض يشبه الإنفلونزا، الإحساس بوخز خفيف أو تنميل الذراعين والساقين، ازدياد<br />حالة الأعراض التنفسية سوءا و/أو طفح (متلازمة شورج-ستروس) . يجب أن تخبر طبيب طفلك فورا إذا&nbsp;<br />حصل لدى طفلك واحد أو أكثر من هذه الأعراض.<br />إذا حصل لدى طفلك أي من الآثار الجانبية، تحدث مع طبيب طفلك، الصيدلي أو الممرض. هذا يشمل أي<br />آثار جانبية غير مذكورة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">يحفظ بعيدا عن متناول الأطفال و نظرهم.<br />لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكورعلى الشريط و العلبة الخارجية.<br />تاريخ الانتهاء يشير إلى اليوم الأخير من ذلك الشهر.<br /><strong>إمكاست &reg;</strong> أقراص قابلة للمضغ :يحفظ بدرجة حرارة دون 30 &deg;م.<br />يجب أن لا يتم التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي<br />عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. وسوف تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ماذا تحتوي أقراص إمكاست &reg;<br />&bull;المادة الفعالة هي مونتيلوكاست (صوديوم) .<br />&bull;المكونات الأخرى هي: ميكروكريستالين سليلوز، لاكتوز مونوهيدرات، مانيتول، كروسكارميلوز<br />الصوديوم، مسحوق نكهة الكرز، أكسيد الحديد الأحمر، أسيسلفام، ستيرات المغنيسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>إمكاست 4 &reg; ملغم أقراص قابلة للمضغ هي أقراص بيضاوية الشكل ذات لون وردي، محدبة الوجهين، محفور على أحد الأوجه MD و M3 على الوجه الآخر، معبأة في أشرطة ألومنيوم/ألومنيوم، معدة للاستعمال عن طريق الفم.<br />حجم العبوة<br />30 قرصا قابل للمضغ. 10 أقراص/شريط، 3 أشرطة/عبوة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">مدينة الدواء للصناعات الدوائية - المملكة العربية السعودية<br />هاتف: 00966920003288<br />فاكس: 00966126358138<br />جوال: 00966555786968<br />ص.ب: 42512 - جدة 21551<br />بريد الكتروني: MD.admin@Axantia.com:&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            07/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Emcast® 4 mg Chewable Tablets.
Montelukast (sodium) 4 mg Chewable Tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Emcast® 4 mg Chewable Tablets: Each tablet contains 4 mg montelukast (sodium). For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Emcast® Chewable Tablets.

Emcast® 4 mg chewable tablets are Pink oval normal biconvex tablets engraved with MD on one face and M3 on the other face, presented in Alu/Alu blisters, intended for oral use.
Pack size:
30 Chewable Tablets. 10 tablets/blister, 3 blisters/pack.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Emcast</strong><strong>&reg;</strong><strong>&nbsp;</strong>is indicated in the treatment of asthma as add-on therapy in those 2 to 5 year old patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom &ldquo;as-needed&rdquo; short-acting &beta;-agonists provide inadequate clinical control of asthma.</p><p dir="ltr"><strong>Emcast</strong><strong>&reg;</strong><strong>&nbsp;</strong>may also be an alternative treatment option to low-dose inhaled corticosteroids for 2 to 5 year old patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids (see section 4.2).</p><p dir="ltr"><strong>Emcast</strong><strong>&reg;</strong><strong>&nbsp;</strong>is also indicated in the prophylaxis of asthma from 2 years of age and older in which the predominant component is exercise-induced bronchoconstriction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Posology</u></p><p dir="ltr">This medicinal product is to be given to a child under adult supervision. For children who have problems consuming a chewable tablet, a granule formulation of montelukast is available. The recommended dose for paediatric patients 2-5 years of age is one 4 mg chewable tablet daily to be taken in the evening. If taken in connection with food, <strong>Emcast</strong><strong>&reg;</strong><strong>&nbsp;</strong>should be taken 1 hour before or 2 hours after food. No dosage adjustment within this age group is necessary.</p><p dir="ltr"><u>General recommendations</u></p><p dir="ltr">The therapeutic effect of <strong>Emcast</strong><strong>&reg;</strong><strong>&nbsp;</strong>on parameters of asthma control occurs within one day. Patients should be advised to continue taking <strong>Emcast</strong><strong>&reg;</strong><strong>&nbsp;</strong>even if their asthma is under control, as well as during periods of worsening asthma.</p><p dir="ltr">No dosage adjustment is necessary for patients with renal insufficiency, or mild to moderate hepatic impairment. There are no data on patients with severe hepatic impairment. The dosage is the same for both male and female patients.<!--[if gte vml 1]><v:group id="_x0000_s1026" style='position:absolute;
 left:0;text-align:left;margin-left:49.7pt;margin-top:16.65pt;width:499.45pt;
 height:.1pt;z-index:-18184;mso-position-horizontal-relative:page'
 coordorigin="994,333" coordsize="9989,2">
 <v:shape id="_x0000_s1027" style='position:absolute;left:994;top:333;width:9989;
  height:2' coordorigin="994,333" coordsize="9989,0" path="m994,333r9988,e"
  filled="f" strokeweight=".94pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="668" height="2" src="file:///C:/Users/Basmah.alrashdi/AppData/Local/Packages/oice_16_974fa576_32c1d314_23b8/AC/Temp/msohtmlclip1/01/clip_image001.gif" /><strong>Emcast</strong><strong>&reg;</strong><strong>&nbsp;</strong>as an alternative treatment option to low-dose inhaled corticosteroids for mild, &nbsp;<u>persistent asthma</u></p><p dir="ltr">Montelukast is not recommended as monotherapy in patients with moderate persistent asthma. The use of montelukast as an alternative treatment option to low-dose inhaled corticosteroids for children with mild persistent asthma should only be considered for patients who do not have a recent history of serious asthma attacks that required oral corticosteroid use and who have demonstrated that they are not capable of using inhaled corticosteroids (see section 4.1). Mild persistent asthma is defined as asthma symptoms more than once a week but less than once a day, nocturnal symptoms more than twice a month but less than once a week, normal lung function between episodes. If satisfactory control of asthma is not achieved at follow-up (usually within one month), the need for an additional or different anti-inflammatory therapy based on the step system for asthma therapy should be evaluated. Patients should be periodically evaluated for their asthma control.</p><p dir="ltr"><!--[if gte vml 1]><v:group id="_x0000_s1028" style='position:absolute;
 left:0;text-align:left;margin-left:49.7pt;margin-top:13.25pt;width:499.45pt;
 height:.1pt;z-index:-18160;mso-position-horizontal-relative:page'
 coordorigin="994,265" coordsize="9989,2">
 <v:shape id="_x0000_s1029" style='position:absolute;left:994;top:265;width:9989;
  height:2' coordorigin="994,265" coordsize="9989,0" path="m994,265r9988,e"
  filled="f" strokeweight=".94pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="668" height="2" src="file:///C:/Users/Basmah.alrashdi/AppData/Local/Packages/oice_16_974fa576_32c1d314_23b8/AC/Temp/msohtmlclip1/01/clip_image002.gif" /><strong>Emcast</strong><strong>&reg;</strong><strong>&nbsp;</strong>as prophylaxis of asthma for 2 to 5 year old patients in whom the predominant &nbsp;<u>component is exercise-induced bronchoconstriction</u></p><p dir="ltr">In 2 to 5 year old patients, exercise-induced bronchoconstriction may be the predominant manifestation of persistent asthma that requires treatment with inhaled corticosteroids. Patients should be evaluated after 2 to 4 weeks of treatment with montelukast. If satisfactory response is not achieved, an additional or different therapy should be considered.</p><p dir="ltr"><!--[if gte vml 1]><v:group id="_x0000_s1030" style='position:absolute;
 left:0;text-align:left;margin-left:49.7pt;margin-top:12.9pt;width:339.45pt;
 height:.1pt;z-index:-18136;mso-position-horizontal-relative:page'
 coordorigin="994,258" coordsize="6789,2">
 <v:shape id="_x0000_s1031" style='position:absolute;left:994;top:258;width:6789;
  height:2' coordorigin="994,258" coordsize="6789,0" path="m994,258r6788,e"
  filled="f" strokeweight=".94pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="455" height="2" src="file:///C:/Users/Basmah.alrashdi/AppData/Local/Packages/oice_16_974fa576_32c1d314_23b8/AC/Temp/msohtmlclip1/01/clip_image003.gif" />Therapy with <strong>Emcast</strong><strong>&reg;</strong><strong>&nbsp;</strong>in relation to other treatments for asthma</p><p dir="ltr">When treatment with <strong>Emcast</strong><strong>&reg;</strong><strong>&nbsp;</strong>is used as add-on therapy to inhaled corticosteroids, <strong>Emcast</strong><strong>&reg;</strong></p><p dir="ltr">should not be abruptly substituted for inhaled corticosteroids (see section 4.4).</p><p dir="ltr">10 mg film-coated tablets are available for adults and adolescents 15 years of age and older.</p><p dir="ltr"><em>Paediatric</em><em> </em><em>population</em></p><p dir="ltr">Do not give <strong>Emcast</strong><strong>&reg;</strong><strong>&nbsp;</strong>4 mg chewable tablets to children less than 2 years of age. The safety and efficacy of <strong>Emcast</strong><strong>&reg;</strong><strong>&nbsp;</strong>4 mg chewable tablets in children less than 2 years of age has not been established.</p><p dir="ltr">5 mg chewable tablets are available for paediatric patients 6 to 14 years of age. &nbsp;<u>Method of administration</u></p><p dir="ltr">Oral use.</p><p dir="ltr">The tablets are to be chewed before swallowing</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Patients should be advised never to use oral montelukast to treat acute asthma attacks and to keep their usual appropriate rescue medication for this purpose readily available. If an acute attack occurs, a short-acting inhaled &beta;-agonist should be used. Patients should seek their doctors&#39; advice as soon as possible if they need more inhalations of short-acting &beta;-agonists than usual.</p><p dir="ltr">Montelukast should not be abruptly substituted for inhaled or oral corticosteroids.</p><p dir="ltr">There are no data demonstrating that oral corticosteroids can be reduced when montelukast is given concomitantly.</p><p dir="ltr">In rare cases, patients on therapy with anti-asthma agents including montelukast may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent</p><p dir="ltr">with Churg-Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy. These cases have been sometimes associated with the reduction or withdrawal of oral corticosteroid therapy. Although a causal relationship with leukotriene receptor antagonism has not been established, physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. Patients who develop these symptoms should be reassessed and their treatment regimens evaluated.</p><p dir="ltr">Treatment with montelukast does not alter the need for patients with aspirin-sensitive asthma to avoid taking aspirin and other non-steroidal anti-inflammatory drugs.</p><p dir="ltr"><strong>Emcast&reg;&nbsp;</strong>4 mg chewable tablets contain Lactose monohydrate, patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Montelukast may be administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma. In drug-interactions studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following medicinal products: theophylline, prednisone, prednisolone, oral contraceptives (ethinyl oestradiol/norethindrone 35/1), terfenadine, digoxin and warfarin.</p><p dir="ltr">The area under the plasma concentration curve (AUC) for montelukast was decreased approximately 40% in subjects with co-administration of phenobarbital. Since montelukast is metabolised by CYP 3A4, 2C8, and 2C9, caution should be exercised, particularly in children, when montelukast is co-administered with inducers of CYP 3A4, 2C8, and 2C9, such as phenytoin, phenobarbital and rifampicin.</p><p dir="ltr"><em>In vitro </em>studies have shown that montelukast is a potent inhibitor of CYP 2C8. However, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of medicinal products primarily metabolised by CYP 2C8) demonstrated that montelukast does not inhibit CYP 2C8 <em>in vivo. </em>Therefore, montelukast is not anticipated to markedly alter the metabolism of medicinal products metabolised by this enzyme (eg., paclitaxel, rosiglitazone, and repaglinide).</p><p dir="ltr"><em>In vitro </em>studies have shown that montelukast is a substrate of CYP 2C8, and to a less significant extent, of 2C9, and 3A4. In a clinical drug-drug interaction study involving montelukast and gemfibrozil (an inhibitor of both CYP 2C8 and 2C9) gemfibrozil increased the systemic exposure of montelukast by 4.4-fold. No routine dosage adjustment of montelukast is required upon co- administration with gemfibrozil or other potent inhibitors of CYP 2C8, but the physician should be aware of the potential for an increase in adverse reactions.</p><p dir="ltr">Based on <em>in vitro </em>data, clinically important drug interactions with less potent inhibitors of CYP 2C8 (e.g., trimethoprim) are not anticipated. Co-administration of montelukast with itraconazole, a strong inhibitor of CYP 3A4, resulted in no significant increase in the systemic exposure of montelukast.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Pregnancy</u></p><p dir="ltr">Animal studies do not indicate harmful effects with respect to effects on pregnancy or embryonal/foetal development.</p><p dir="ltr">Limited data from available pregnancy databases do not suggest a causal relationship between montelukast and malformations (i.e. limb defects) that have been rarely reported in worldwide post-marketing experience.</p><p dir="ltr"><strong>Emcast</strong><strong>&reg;</strong><strong>&nbsp;</strong>may be used during pregnancy only if it is considered to be clearly essential. &nbsp;<u>Breast-feeding</u></p><p dir="ltr">Studies in rats have shown that montelukast is excreted in milk (see section 5.3). It is unknown whether montelukast/metabolites are excreted in human milk.</p><p dir="ltr"><strong>Emcast</strong><strong>&reg;</strong><strong>&nbsp;</strong>may be used in breast-feeding mothers only if it is considered to be clearly essential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Emcast</strong><strong>&reg;</strong><strong>&nbsp;&nbsp;</strong>has no or negligible influence on the ability to drive and use machines. However, individuals have reported drowsiness or dizziness.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Montelukast has been evaluated in clinical studies in patients with persistent asthma as follows:</p><p dir="ltr">&bull;&nbsp; 10 mg film-coated tablets in approximately 4,000 adult and adolescent patients 15 years of age and older</p><p dir="ltr">&bull;&nbsp; 5 mg chewable tablets in approximately 1,750 paediatric patients 6 to 14 years of age, and</p><p dir="ltr">&bull;&nbsp; 4 mg chewable tablets in 851 paediatric patients 2 to 5 years of age.</p><p dir="ltr">Montelukast has been evaluated in a clinical study in patients with intermittent asthma as follows:</p><p dir="ltr">&bull;&nbsp; 4 mg granules and chewable tablets in 1,038 paediatric patients 6 months to 5 years of age The following drug-related adverse&nbsp; reactions in&nbsp; clinical studies were&nbsp; reported commonly (&ge;1/100 to &lt;1/10) in patients treated with montelukast and at a greater incidence than in patients treated with placebo:</p><p dir="ltr">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" dir="ltr"><tbody><tr><td rowspan="6" style="vertical-align:top"><p><strong>Body</strong><strong> </strong><strong>System Class</strong></p></td><td style="vertical-align:top"><p><strong>Adult</strong><strong> </strong><strong>and Adolescent</strong></p></td><td style="vertical-align:top"><p><strong>Paediatric</strong><strong> &nbsp;Patients &nbsp;6</strong></p></td><td style="vertical-align:top"><p><strong>Paediatric</strong><strong> &nbsp;Patients &nbsp;2</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Patients</strong><strong> </strong><strong>15 years and</strong></p></td><td style="vertical-align:top"><p><strong>to 14 years old</strong></p></td><td style="vertical-align:top"><p><strong>to 5 years old</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>older</strong></p></td><td style="vertical-align:top"><p><strong>(one</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>8-week</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>study;</strong></p></td><td style="vertical-align:top"><p><strong>(one</strong><strong> &nbsp;12-week &nbsp;study;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>(two 12-week studies;</strong></p></td><td style="vertical-align:top"><p><strong>n=201)</strong></p></td><td style="vertical-align:top"><p><strong>n=461)</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>n=795)</strong></p></td><td style="vertical-align:top"><p><strong>(two 56 week studies;</strong></p></td><td style="vertical-align:top"><p><strong>(one</strong><strong> &nbsp;48-week &nbsp;study;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>n=615)</strong></p></td><td style="vertical-align:top"><p><strong>n=278)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>system</strong><strong> </strong><strong>disorders</strong></p></td><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastro-intestinal</strong><strong> </strong><strong>disorders</strong></p></td><td style="vertical-align:top"><p>abdominal pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>abdominal pain</p></td></tr><tr><td style="vertical-align:top"><p><strong>General</strong><strong> </strong><strong>disorders</strong><strong> </strong><strong>and</strong><strong> </strong><strong>administration site</strong><strong> </strong><strong>conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>thirst</p></td></tr></tbody></table><p dir="ltr">With prolonged treatment in clinical trials with a limited number of patients for up to 2 years for adults, and up to 12 months for paediatric patients 6 to 14 years of age, the safety profile did not change.</p><p dir="ltr">Cumulatively, 502 paediatric patients 2 to 5 years of age were treated with montelukast for at least 3 months, 338 for 6 months or longer, and 534 patients for 12 months or longer. With prolonged treatment, the safety profile did not change in these patients either.</p><p dir="ltr"><u>Tabulated list of Adverse Reactions</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Adverse reactions reported in post-marketing use are listed, by System Organ Class and specific Adverse Reactions, in the table below. Frequency Categories were estimated based on relevant clinical trials.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System Organ Class</strong></p></td><td><p><strong>Adverse Reactions</strong></p></td><td><p><strong>Frequency Category*</strong></p></td></tr><tr><td><p>Infections and infestations</p></td><td><p>upper respiratory infection</p></td><td><p>Very Common</p></td></tr><tr><td><p>Blood and lymphatic system</p><p>disorders</p></td><td><p>increased bleeding tendency</p></td><td><p>Rare</p></td></tr><tr><td rowspan="2"><p>Immune system disorders</p></td><td><p>hypersensitivity reactions including</p><p>anaphylaxis</p></td><td><p>Uncommon</p></td></tr><tr><td><p>hepatic eosinophilic infiltration</p></td><td><p>Very Rare</p></td></tr><tr><td rowspan="3"><p>Psychiatric disorders</p></td><td><p>dream abnormalities including</p><p>nightmares, insomnia,</p><p>somnambulism, anxiety, agitation</p><p>including aggressive behaviour or</p><p>hostility, depression, psychomotor</p><p>hyperactivity (including irritability,</p><p>restlessness, tremor&sect;)</p></td><td><p>Uncommon</p></td></tr><tr><td><p>disturbance in attention, memory</p><p>impairment</p></td><td><p>Rare</p></td></tr><tr><td><p>hallucinations, disorientation, suicidal</p><p>thinking and behaviour (suicidality)</p></td><td><p>Very Rare</p></td></tr><tr><td><p>Nervous system disorders</p></td><td><p>dizziness, drowsiness,</p><p>paraesthesia /hypoesthesia, seizure</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Cardiac disorders</p></td><td><p>palpitations</p></td><td><p>Rare</p></td></tr><tr><td rowspan="3"><p>Respiratory, thoracic and</p><p>mediastinal disorders</p></td><td><p>epistaxis</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Churg-Strauss Syndrome (CSS) (see section 4.4)</p></td><td><p>Very Rare</p></td></tr><tr><td><p>pulmonary eosinophilia</p></td><td><p>Very Rare</p></td></tr><tr><td rowspan="2"><p>Gastrointestinal disorders</p></td><td><p>diarrhoea, nausea, vomiting</p></td><td><p>Common</p></td></tr><tr><td><p>dry mouth, dyspepsia</p></td><td><p>Uncommon</p></td></tr><tr><td rowspan="2"><p>Hepatobiliary disorders</p></td><td><p>elevated levels of serum</p><p>transaminases (ALT, AST)</p></td><td><p>Common</p></td></tr><tr><td><p>hepatitis (including cholestatic,</p><p>hepatocellular, and mixed-pattern liver injury)</p></td><td><p>Very Rare</p></td></tr><tr><td rowspan="4"><p>Skin and subcutaneous tissue</p><p>disorders</p></td><td><p>rash</p></td><td><p>Common</p></td></tr><tr><td><p>bruising, urticaria, pruritus</p></td><td><p>Uncommon</p></td></tr><tr><td><p>angiooedema</p></td><td><p>Rare</p></td></tr><tr><td><p>erythema nodosum, erythema</p><p>multiforme</p></td><td><p>Very Rare</p></td></tr><tr><td><p>Musculoskeletal and connectivetissue disorders</p></td><td><p>arthralgia, myalgia including muscle cramps</p></td><td><p>Uncommon</p></td></tr><tr><td rowspan="2"><p>General disorders and</p><p>administration site conditions</p></td><td><p>pyrexia</p></td><td><p>Common</p></td></tr><tr><td><p>asthenia/fatigue, malaise, oedema</p></td><td><p>Uncommon</p></td></tr><tr><td colspan="3"><p>*Frequency Category: Defined for each Adverse Reaction by the incidence reported in the</p><p>clinical trials data base: Very Common (&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon</p><p>(&ge;1/1,000 to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1,000), Very Rare (&lt;1/10,000).</p><p>&dagger;This adverse experience, reported as Very Common in the patients who received montelukast,</p><p>was also reported as Very Common in the patients who received placebo in clinical trials.</p><p>&Dagger;This adverse experience, reported as Common in the patients who received montelukast, was</p><p>also reported as Common in the patients who received placebo in clinical trials.</p><p>&sect; Frequency Category: Rare</p></td></tr></tbody></table><p dir="ltr"><strong>To</strong><strong> report</strong><strong> </strong><strong>any</strong><strong> </strong><strong>side</strong><strong> </strong><strong>effect(s):</strong></p><p dir="ltr"><strong>&bull;Saudi</strong><strong> </strong><strong>Arabia:</strong></p><p dir="ltr">The National Pharmacovigilance and Drug Safety Center (NPC): Fax: +966-11-205-7662</p><p dir="ltr">Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p dir="ltr">Reporting hotline: 19999</p><p dir="ltr">E-mail: npc.drug@sfda.gov.sa Website: www.sfda.gov.sa/npc</p><p dir="ltr"><strong>&bull;Other GCC States:</strong></p><p dir="ltr">Please contact the relevant competent authority.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">In chronic asthma studies, montelukast has been administered at doses up to 200 mg/day to adult patients for 22 weeks and in short-term studies, up to 900 mg/day to patients for approximately one week without clinically important adverse experiences.</p><p dir="ltr">There have been reports of acute overdose in post-marketing experience and clinical studies with montelukast. These include reports in adults and children with a dose as high as 1,000 mg (approximately 61 mg/kg in a 42 month old child). The clinical and laboratory findings observed were consistent with the safety profile in adults and paediatric patients. There were no adverse experiences in the majority of overdose reports.</p><p dir="ltr"><u>Symptoms of overdose</u></p><p dir="ltr">The most frequently occurring adverse experiences were consistent with the safety profile of montelukast and included abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity.</p><p dir="ltr"><u>Management of overdose</u></p><p dir="ltr">No specific information is available on the treatment of overdose with montelukast. It is not known whether montelukast is dialysable by peritoneal- or haemo-dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmacotherapeutic group: Leukotriene receptor antagonist ATC-Code: R03D C03</p><p dir="ltr"><u>Mechanism of action</u></p><p dir="ltr">The&nbsp;cysteinyl&nbsp;leukotrienes&nbsp;(LTC4, LTD4,&nbsp;LTE4)&nbsp;are potent inflammatory eicosanoids released&nbsp;from various cells including mast cells and eosinophils. These important pro-asthmatic mediators bind to cysteinyl leukotriene receptors (CysLT) found in the human airway and cause airway actions, including bronchoconstriction, mucous secretion, vascular permeability, and eosinophil recruitment.</p><p dir="ltr"><u>Pharmacodynamic effects</u></p><p dir="ltr">Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. In clinical studies, montelukast inhibits bronchoconstriction due to inhaled&nbsp;LTD4 at doses as low as 5 mg. Bronchodilation was observed within 2 hours of oral&nbsp;administration. The bronchodilation effect caused by a &beta;-agonist was additive to that caused by montelukast. Treatment with montelukast inhibited both early- and late-phase bronchoconstriction due to antigen challenge. Montelukast, compared with placebo, decreased peripheral blood eosinophils in adult and paediatric patients. In a separate study, treatment with montelukast significantly decreased eosinophils in the airways (as measured in sputum). In adult and paediatric patients 2 to 14 years of age, montelukast, compared with placebo, decreased peripheral blood eosinophils while improving clinical asthma control.</p><p dir="ltr"><u>Clinical efficacy and safety</u></p><p dir="ltr">In studies in adults, montelukast, 10 mg once daily, compared with placebo, demonstrated significant&nbsp;improvements&nbsp;in&nbsp;morning FEV1 (10.4%&nbsp;vs&nbsp;2.7% change from baseline), AM peak&nbsp;expiratory flow rate (PEFR) (24.5 L/min vs 3.3 L/min change from baseline), and significant decrease in total &beta;-agonist use (-26.1% vs -4.6% change from baseline). Improvement in patient-reported daytime and nighttime asthma symptoms scores was significantly better than placebo.</p><p dir="ltr">Studies in adults demonstrated the ability of montelukast to add to the clinical effect of inhaled corticosteroid (% change from baseline for inhaled beclomethasone plus montelukast vs beclomethasone,&nbsp;respectively&nbsp;for FEV1: 5.43%&nbsp;vs&nbsp;1.04%; &beta;-agonist use: -8.70% vs 2.64%).&nbsp;Compared with inhaled beclomethasone (200 &mu;g twice daily with a spacer device), montelukast demonstrated a more rapid initial response, although over the 12-week study, beclomethasone provided a greater average treatment effect (% change from baseline for montelukast vs beclomethasone,&nbsp;respectively&nbsp;for FEV1:7.49%&nbsp;vs&nbsp;13.3%; &beta;-agonist use: -28.28% vs -43.89%).&nbsp;However, compared with beclomethasone, a high percentage of patients treated with montelukast achieved similar clinical responses (e.g., 50% of patients treated with beclomethasone&nbsp;achieved&nbsp;an improvement in FEV1 of&nbsp;approximately&nbsp;11% or more over&nbsp;baseline while approximately 42% of patients treated with montelukast achieved the same response).</p><p dir="ltr">In a 12-week, placebo-controlled study in paediatric patients 2 to 5 years of age, montelukast 4 mg once daily improved parameters of asthma control compared with placebo irrespective of concomitant controller therapy (inhaled/nebulised corticosteroids or inhaled/nebulised sodium</p><p dir="ltr">cromoglycate). Sixty percent of patients were not on any other controller therapy. Montelukast improved daytime symptoms (including coughing, wheezing, trouble breathing and activity limitation) and nighttime symptoms compared with placebo. Montelukast also decreased &ldquo;as needed&rdquo; &beta;-agonist use and corticosteroid rescue for worsening asthma compared with placebo. Patients receiving montelukast had more days without asthma than those receiving placebo. A treatment effect was achieved after the first dose.</p><p dir="ltr">In a 12-month, placebo-controlled study in paediatric patients 2 to 5 years of age with mild asthma and episodic exacerbations, montelukast 4 mg once daily significantly (p&le;0.001) reduced the yearly rate of asthma exacerbation episodes (EE) compared with placebo (1.60 EE vs. 2.34 EE, respectively), [EE defined as &ge;3 consecutive days with daytime symptoms requiring &beta;-agonist use, or corticosteroids (oral or inhaled), or hospitalisation for asthma]. The percentage reduction in yearly EE rate was 31.9%, with a 95% CI of 16.9, 44.1.</p><p dir="ltr">In a placebo-controlled study in paediatric patients 6 months to 5 years of age who had intermittent asthma but did not have persistent asthma, treatment with montelukast was administered over a 12-month period, either as a once-daily 4 mg regimen or as a series of 12- day courses that each were started when an episode of intermittent symptoms began. No significant difference was observed between patients treated with montelukast 4 mg or placebo in the number of asthma episodes culminating in an asthma attack, defined as an asthma episode requiring utilization of health-care resources such as an unscheduled visit to a doctor&#39;s office, emergency room, or hospital; or treatment with oral, intravenous, or intramuscular corticosteroid.</p><p dir="ltr">In an 8-week study in paediatric patients 6 to 14 years of age, montelukast 5 mg once daily, compared&nbsp;with&nbsp;placebo,&nbsp;significantly&nbsp;improved&nbsp;respiratory&nbsp;function&nbsp;(FEV1 8.71%&nbsp;vs&nbsp;4.16%&nbsp;change from baseline; AM PEFR 27.9 L/min vs 17.8 L/min change&nbsp; from baseline) and decreased &ldquo;as-needed&rdquo; &beta;-agonist use (-11.7% vs +8.2% change from baseline).</p><p dir="ltr">In a 12-month study comparing the efficacy of montelukast to inhaled fluticasone on asthma control in paediatric patients 6 to 14 years of age with mild persistent asthma, montelukast was non-inferior to fluticasone in increasing the percentage of asthma rescue-free days (RFDs), the primary endpoint. Averaged over the 12-month treatment period, the percentage of asthma RFDs increased from 61.6 to 84.0 in the montelukast group and from 60.9 to 86.7 in the fluticasone group. The between group difference in LS mean increase in the percentage of asthma RFDs was statistically significant (-2.8 with a 95% CI of -4.7, -0.9), but within the limit pre-defined to be clinically not inferior. Both montelukast and fluticasone also improved asthma control on secondary variables assessed over the 12 month treatment period:</p><p dir="ltr">FEV1 increased&nbsp;from&nbsp;1.83&nbsp;L to 2.09 L in the montelukast group and from 1.85 L to 2.14 L in the&nbsp;fluticasone&nbsp;group.&nbsp;The&nbsp;between-group&nbsp;difference&nbsp;in&nbsp;LS mean increase in FEV1 was&nbsp;-0.02 L with&nbsp;a 95% CI of -0.06, 0.02. The mean increase from baseline in % predicted FEV1 was&nbsp;0.6% in the&nbsp;montelukast treatment group, and 2.7% in the fluticasone treatment group. The difference in LS means&nbsp;for the change from baseline in the % predicted FEV1 was&nbsp;significant:&nbsp;-2.2%&nbsp;with&nbsp;a 95%&nbsp;CI of -3.6, -0.7.</p><p dir="ltr">The percentage of days with &beta;-agonist use decreased from 38.0 to 15.4 in the montelukast group, and from 38.5 to 12.8 in the fluticasone group. The between group difference in LS means for the percentage of days with &beta;-agonist use was significant: 2.7 with a 95% CI of 0.9, 4.5.</p><p dir="ltr">The percentage of patients with an asthma attack (an asthma attack being defined as a period of worsening asthma that required treatment with oral steroids, an unscheduled visit to the</p><p dir="ltr">doctor&#39;s office, an emergency room visit, or hospitalisation) was 32.2 in the montelukast group and 25.6 in the fluticasone group; the odds ratio (95% CI) being significant: equal to 1.38 (1.04, 1.84).</p><p dir="ltr">The percentage of patients with systemic (mainly oral) corticosteroid use during the study period was 17.8% in the montelukast group and 10.5% in the fluticasone group. The between group difference in LS means was significant: 7.3% with a 95% CI of 2.9; 11.7.</p><p dir="ltr">Significant reduction of exercise-induced bronchoconstriction (EIB) was demonstrated in a 12- week&nbsp;study in adults (maximal fall in FEV1 22.33%&nbsp;for montelukast vs 32.40% for placebo; time&nbsp;to recovery to within 5% of baseline FEV144.22 min vs 60.64 min). This effect was consistent&nbsp;throughout the 12-week study period. Reduction in EIB was also demonstrated in a short term study in paediatric patients 6 to 14 years of age (maximal fall in FEV1 18.27% vs&nbsp;26.11%; time&nbsp;to recovery to within 5% of baseline FEV1 17.76&nbsp;min&nbsp;vs&nbsp;27.98&nbsp;min).&nbsp;The effect in both studies&nbsp;was demonstrated at the end of the once-daily dosing interval.</p><p dir="ltr">In aspirin-sensitive asthmatic patients receiving concomitant inhaled and/or oral corticosteroids, treatment with montelukast, compared with placebo, resulted in significant improvement in asthma control (FEV1 8.55% vs -1.74% change from baseline and decrease in total &beta;-agonist&nbsp;use -27.78% vs 2.09% change from baseline).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Absorption</u></p><p dir="ltr">Montelukast is rapidly absorbed following oral administration. For the 10 mg film-coated tablet, the mean peak plasma concentration (Cmax)&nbsp;is&nbsp;achieved&nbsp;3 hours (Tmax)&nbsp;after administration in&nbsp;adults in the fasted state. The mean oral bioavailability is 64%. The oral bioavailability and Cmax are not influenced by a standard meal. Safety and efficacy were demonstrated in clinical&nbsp;trials where the 10 mg film-coated tablet was administered without regard to the timing of food ingestion.</p><p dir="ltr">For the 5 mg chewable tablet, the Cmax is&nbsp;achieved&nbsp;in&nbsp;2 hours after administration in adults in&nbsp;the fasted state. The mean oral bioavailability is 73% and is decreased to 63% by a standard meal.</p><p dir="ltr">After administration of the 4 mg chewable tablet to paediatric patients 2 to 5 years of age in the fasted state, Cmax is&nbsp;achieved&nbsp;2 hours after administration. The mean Cmax is&nbsp;66% higher while&nbsp;mean Cmin is lower than&nbsp;in adults receiving a 10 mg tablet.</p><p dir="ltr"><u>Distribution</u></p><p dir="ltr">Montelukast is more than 99% bound to plasma proteins. The steady-state volume of distribution of montelukast averages 8-11 litres. Studies in rats with radiolabelled montelukast indicate minimal distribution across the blood-brain barrier. In addition, concentrations of radiolabelled material at 24 hours post-dose were minimal in all other tissues.</p><p dir="ltr"><u>Biotransformation</u></p><p dir="ltr">Montelukast is extensively metabolised. In studies with therapeutic doses, plasma concentrations of metabolites of montelukast are undetectable at steady state in adults and children.</p><p dir="ltr">Cytochrome P450 2C8 is the major enzyme in the metabolism of montelukast. Additionally CYP 3A4 and 2C9 may have a minor contribution, although itraconazole, an inhibitor of CYP 3A4, was shown not to change pharmacokinetic variables of montelukast in healthy subjects that received 10 mg montelukast daily. Based on <em>in vitro </em>results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9,</p><p dir="ltr">1A2, 2A6, 2C19, or 2D6. The contribution of metabolites to the therapeutic effect of montelukast is minimal.</p><p dir="ltr"><u>Elimination</u></p><p dir="ltr">The plasma clearance of montelukast averages 45 ml/min in healthy adults. Following an oral dose of radiolabelled montelukast, 86% of the radioactivity was recovered in 5-day faecal collections and &lt;0.2% was recovered in urine. Coupled with estimates of montelukast oral bioavailability, this indicates that montelukast and its metabolites are excreted almost exclusively via the bile.</p><p dir="ltr"><u>Characteristics in Patients</u></p><p dir="ltr">No dosage adjustment is necessary for the elderly or mild to moderate hepatic insufficiency. Studies in patients with renal impairment have not been undertaken. Because montelukast and its metabolites are eliminated by the biliary route, no dose adjustment is anticipated to be necessary in patients with renal impairment. There are no data on the pharmacokinetics of montelukast in patients with severe hepatic insufficiency (Child-Pugh score &gt;9).</p><p dir="ltr">With high doses of montelukast (20- and 60-fold the recommended adult dose), a decrease in plasma theophylline concentration was observed. This effect was not seen at the recommended dose of 10 mg once daily.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">In animal toxicity studies, minor serum biochemical alterations in ALT, glucose, phosphorus and triglycerides were observed which were transient in nature. The signs of toxicity in animals were increased excretion of saliva, gastro-intestinal symptoms, loose stools and ion imbalance. These occurred at dosages which provided &gt;17-fold the systemic exposure seen at the clinical dosage. In monkeys, the adverse effects appeared at doses from 150 mg/kg/day (&gt;232-fold the systemic exposure seen at the clinical dose). In animal studies, montelukast did not affect fertility or reproductive performance at systemic exposure exceeding the clinical systemic exposure by greater than 24-fold. A slight decrease in pup body weight was noted in the female fertility study in rats at 200 mg/kg/day (&gt;69-fold the clinical systemic exposure). In studies in rabbits, a higher incidence of incomplete ossification, compared with concurrent control animals, was seen at systemic exposure &gt;24-fold the clinical systemic exposure seen at the clinical dose. No abnormalities were seen in rats. Montelukast has been shown to cross the placental barrier and is excreted in breast milk of animals.</p><p dir="ltr">No deaths occurred following a single oral administration of montelukast (sodium) at doses up to 5,000 mg/kg in mice and rats (15,000 mg/m2 and 30,000 mg/m2 in mice and rats, respectively), the maximum dose tested. This dose is equivalent to 25,000 times the recommended daily adult human dose (based on an adult patient weight of 50 kg).</p><p dir="ltr">Montelukast was determined not to be phototoxic in mice for UVA, UVB or visible light spectra at doses up to 500 mg/kg/day (approximately &gt;200-fold based on systemic exposure).</p><p dir="ltr">Montelukast was neither mutagenic in <em>in vitro </em>and <em>in vivo </em>tests nor tumorigenic in rodent species.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Microcrystalline cellulose (Avicel) PH102, lactose monohydrate, mannitol EZ, croscarmellose sodium, cherry powder flavor, red iron oxide, acesulfame K, magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><strong>Emcast</strong><strong>&reg;</strong><strong>&nbsp;4 mg chewable tablets are </strong>Pink oval normal biconvex tablets engraved with MD on one face and M3 on the other face, presented in Alu/Alu blisters, intended for oral use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Med City Pharma - KSA 
Tel: 00966920003288
Fax: 00966126358138
Mobile: 00966555786968
P.O .Box: 42512 - Jeddah 21551
E-mail: MD.admin@Axantia.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07/2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>